Peptide Treatments in Clinical Trials 2024 2025
Peptide Treatments for Crohn's Disease
Synthetic peptides Crohn's disease treatment clinical trials 10 results
Peptide treatments for Crohn's disease represent an emerging area of therapeutic research with several promising approaches currently under investigation. Here's a summary of current evidence:
GLP-1 Receptor Agonists
The Helmsley Charitable Trust recently funded research ($3 million in December 2024) to study GLP-1 receptor agonists for intestinal healing in severe Crohn's disease. GLP-1 Medications: Reimagining the Treatment Paradigm for Severe Crohn's Disease These glucagon-like peptides and DPP-IV inhibitors have shown promise in IBD research, with animal studies indicating that GLP treatment may improve colitis.
Synthetic Peptide Therapies
Several synthetic peptides are being developed specifically for inflammatory bowel disease:
Anti-inflammatory Peptide Amphiphiles (PAs): Northwestern University researchers have shown that direct injection of these peptides into intestinal lesions can reduce inflammation and lesion size in animal models of Crohn's disease. Novel injectable therapy shows promise in treating Crohn's disease: Center for Regenerative Nanomedicine (CRN) - Northwestern University
NIPEP-IBD: This synthetic peptide targets integrin beta 1 to restore intestinal epithelial cells for IBD treatment. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease | PNAS
Engineered Cyclic Peptides: Small peptides have shown promise in reducing inflammation in IBD models, with engineered cyclic peptides demonstrating symptom relief in mouse studies. Twelve‐week peptide‐based formula therapy may be effective in inducing remission of active Crohn disease among women who are pregnant or preparing for pregnancy - Yang - 2022 - Nutrition in Clinical Practice - Wiley Online Library
Immunomodulatory Peptides
WKYMVm: This immune-stimulating peptide has shown therapeutic effects by decreasing intestinal permeability. It works by stimulating colon epithelial cell growth and reducing inflammatory cytokine production. Frontiers | Design and Development of a Novel Peptide for Treating Intestinal Inflammation
Cortistatin: This cyclic neuropeptide related to somatostatin has emerged as a potential anti-inflammatory agent with therapeutic benefits in inflammatory bowel disease.
Peptide-Based Nutritional Therapy
A 12-week peptide-based formula therapy showed effectiveness in inducing remission in active Crohn's disease. In clinical studies, 85.7% of patients achieved remission with significant decreases in disease activity scores. NIPEP-IBD; A SYNTHETIC PEPTIDE TARGETING NOVEL MOLECULE, INTEGRIN BETA 1, TO RESTITUTE INTESTINAL EPITHELIAL CELLS FOR INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT | Inflammatory Bowel Diseases | Oxford Academic
Most of these peptide treatments remain in preclinical or early clinical development. While conventional biologic therapies are still the standard care for moderate to severe Crohn's disease, these peptide-based approaches offer promising new mechanisms that could complement or improve existing treatments. If you're interested in peptide treatments, consult with a gastroenterologist who can guide you on appropriate clinical trials or emerging therapies for your specific situation.